- Moderna takes advantage of FDA boon for Merck-linked cancer vaccineInvestor’s Business Daily
- Moderna’s Skin Cancer Combination Therapy Receives Groundbreaking FDA LabelReuters
- Moderna expands CRISPR gene editing research with ElevateBio partnershipThe Boston Globe
- Moderna taps Life Edit to develop next-generation gene therapiesFierceBiotech
- Moderna and Merck announce that mRNA-4157/V940, an investigational personalized mRNA-based cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab), has received FDA Breakthrough Therapy Designation for the adjuvant treatment of patientsYahoo finance
- See full coverage on Google News